Fundraising Fox
/Companies
Sign in

Ankasa Regenerative Therapeutics

La Jolla, US · Founded 2014 · Delaware corporation · 2 known investors

Find your way into Ankasa Regenerative Therapeutics

Sign up to find every way you can get introduced to Ankasa Regenerative Therapeutics

  • Your email: who you already know at Ankasa Regenerative Therapeutics, and who your contacts know
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Ankasa Regenerative Therapeutics team
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Sign up with GoogleAlready have an account? Log in

Ankasa is developing ART352-L, a regenerative medicine designed to enhance bone formation in reconstructive surgeries, with initial focus on spinal fusion procedures to treat degenerative disc disease. The therapy aims to improve healing outcomes and reduce revision surgeries for patients requiring bone reconstruction.

BiotechLongevityMedical Devices

Founders & leadership

Ankasa Regenerative Therapeutics was founded in 2014 by Sanford J. Madigan, Ph.D. and Jill A. Helms, D.D.S., Ph.D..

SJ
Sanford J. Madigan, Ph.D.Co-Founder, Chief Executive Officer
JA
Jill A. Helms, D.D.S., Ph.D.Co-founder, Former CSO, currently Senior Advisor
DD
Douglas DownsExecutive
SJ
Sanford J. MadiganCEO

Board

KK
Kevin KinsellaBoard director

Investors · 2

Stanford University✓ confirmed by Ankasa Regenerative TherapeuticsStanford

How we know: the company's own site · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$15.5M disclosed across 2 rounds · 2015–2020

▶$6MraisedOct 2020 · 4 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Sanford J. MadiganExecutive Officer, Director
  • Kevin KinsellaDirector
  • Andre Kobelt, Ph.D.Director
  • Tighe ReardonExecutive Officer
Offering amount
$12M
Amount sold
$6M
First sale
Sep 2020
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$9.5MraisedAug 2015 · 5 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Douglas DownsExecutive Officer, Director
  • Kevin KinsellaDirector
  • Sanford J. MadiganExecutive Officer, Director
Offering amount
$20M
Amount sold
$9.5M
First sale
May 2015
Incorporated
Corporation, Delaware, 2014
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

What does Ankasa Regenerative Therapeutics do?
Ankasa is developing ART352-L, a regenerative medicine designed to enhance bone formation in reconstructive surgeries, with initial focus on spinal fusion procedures to treat degenerative disc disease. The therapy aims to improve healing outcomes and reduce revision surgeries for patients requiring bone reconstruction.
Who founded Ankasa Regenerative Therapeutics?
Ankasa Regenerative Therapeutics was founded by Sanford J. Madigan, Ph.D., Jill A. Helms, D.D.S., Ph.D. in 2014.
Who are Ankasa Regenerative Therapeutics's investors?
Ankasa Regenerative Therapeutics's investors include Correlation Ventures, Stanford University.
How much funding has Ankasa Regenerative Therapeutics raised?
Ankasa Regenerative Therapeutics has disclosed $15.5M raised across 2 rounds.
Where is Ankasa Regenerative Therapeutics headquartered?
Ankasa Regenerative Therapeutics is headquartered in La Jolla, US.